Does the Merged 3D Imaging Improve Contact Force and Long Term Procedure Outcome in Atrial Fibrillation?
Launched by KOREA UNIVERSITY GURO HOSPITAL · Nov 17, 2017
Trial Information
Current as of September 12, 2025
Completed
Keywords
ClinConnect Summary
In a recent study, ablation therapy of AF was superior to antiarrhythmic drug therapy alone in preventing atrial arrhythmia recurrences in patients with paroxysmal or persistent AF. Various techniques have been proposed and are currently under investigation in various electrophysiology laboratories, with increasing knowledge of the pathophysiology of human AF and critical assessment of clinical outcome after the procedure. The factors related with the technical success involves appropriate contact force between catheter tip and target tissue for the complete electrical blockade and transmur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing first-time catheter ablation for AF.
- • Willing and able to provide informed consent
- • Age greater than or equal to 18 years.
- Exclusion Criteria:
- • Patients who have previously undergone AF ablation
- • Patients with more than mild mitral valve stenosis or mechanical mitral valve replacement
- • Patients with chronic renal impairment with creatinine clearance rate of \< 50
About Korea University Guro Hospital
Korea University Guro Hospital is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative clinical research and trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge medical technology with a multidisciplinary approach to patient care, ensuring the highest standards of safety and efficacy in research. With a focus on a wide array of therapeutic areas, Korea University Guro Hospital is dedicated to contributing to the global medical community by fostering collaboration and promoting evidence-based practices that enhance patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Guro Gu, Korea, Republic Of
Bucheon, Korea, Republic Of
Patients applied
Trial Officials
Hong Euy Lim, MD, PhD
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials